The drug, informally called "reta," works by activating three hormone receptors simultaneously — GLP-1, GIP and glucagon — a triple-action mechanism that distinguishes it from the dual-agonist drugs already on the market. According to Everyday Health's reporting on the newly published research, participants also achieved meaningful improvements in blood-sugar control, which matters separately from the weight figure: type 2 diabetes and obesity often compound each other's harms, and a treatment that addresses both at once has a different profile from one that addresses either alone.
What the trial does not yet establish is how retatrutide performs over the longer term, how its safety profile compares at scale, or whether the weight loss is sustained after participants stop taking it — questions that have trailed the entire GLP-1 class and remain unanswered here. This was a phase 2 study, meaning it was designed primarily to assess dosing and early signals rather than to confirm efficacy across a large, representative population. The move to phase 3, if it comes, will carry those questions with it.
Marcus Azzopardi 
Ryan C 
Gabriel Fenech